Trial Profile
A phase I/II clinical trial with cell therapy treatment to significantly reduce the need for immune suppression treatment for both donor-matched and mismatched bone marrow transplant patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Stem cell therapies (Primary)
- Indications Bone marrow transplant rejection; Engraftment
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2015 According to a company media release, Cell Source expects to use the same treatment protocol in this study that was used in the initial study conducted by the University of Parma (see CT profile 700263936).
- 12 Aug 2014 New trial record